Human antibody technology and the development of antibodies against cytomegalovirus

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 153-170

  Ohlin, Mats ^a   Söderberg Nauclér, Cecilia ^b  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytomegalovirus; Glycoprotein B; Glycoprotein H; Human monoclonal antibody; Pentameric complex; Therapeutic monoclonal antibody; Virus neutralization

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN; GLYCOPROTEIN B; GLYCOPROTEIN H; GLYCOPROTEIN M; GLYCOPROTEIN N; HUMAN MONOCLONAL ANTIBODY; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ANTIGEN ANTIBODY COMPLEX; MONOCLONAL ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION CONTROL; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS REACTIVATION; ANTIGEN ANTIBODY COMPLEX; CHEMICAL STRUCTURE; CHEMISTRY; CYTOMEGALOVIRUS INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; VIROLOGY;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY; MODELS, MOLECULAR; VIRAL ENVELOPE PROTEINS;

EID: 84939267590     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.02.026     Document Type: Review

References (272)

1. 4-Antibody Infectious Disease - Hcmv 2014, http://www.4-antibody.com/pipeline/infectious_disease/hcmv.cfm.
2. Adler B., Scrivano L., Ruzcics Z., Rupp B., Sinzger C., Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J. Gen. Virol. 2006, 87:2451-2460.
3. Ahlfors K., Harris S., Ivarsson S., Svanberg L. Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N. Engl. J. Med. 1981, 305:284.
4. AIDS-Clinical-Trials-Group MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch. Ophthalmol. 1997, 115:1528-1536.
5. Aiello A.E., Simanek A.M. Cytomegalovirus and immunological aging: the real driver of HIV and heart disease. J. Infect. Dis. 2012, 205:1772-1774.
6. AIMM Therapeutics Pipeline 2014, http://www.aimmtherapeutics.com/index.php/pipeline.
7. Alexander H., Harpprecht J., Podzuweit H.G., Rautenberg P., Muller-Ruchholtz W. Human monoclonal antibodies recognize early and late viral proteins of human cytomegalovirus. Hum. Antib. Hybrid. 1994, 5:81-90.
8. Alonso Arias R., Moro-Garcia M.A., Echeverria A., Solano-Jaurrieta J.J., Suarez-Garcia F.M., Lopez-Larrea C. Intensity of the humoral response to cytomegalovirus is associated with the phenotypic and functional status of the immune system. J. Virol. 2013, 87:4486-4495.
9. Andersen J.T., Daba M.B., Berntzen G., Michaelsen T.E., Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 2010, 285:4826-4836.
10. Atabani S.F., Smith C., Atkinson C., Aldridge R.W., Rodriguez-Peralvarez M., Rolando N., Harber M., Jones G., O'Riordan A., Burroughs A.K., Thorburn D., O'Beirne J., Milne R.S., Emery V.C., Griffiths P.D. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am. J. Transplant. 2012, 12:2457-2464.
11. Auerbach M.R., Yan D., Vij R., Hongo J.A., Nakamura G., Vernes J.M., Meng Y.G., Lein S., Chan P., Ross J., Carano R., Deng R., Lewin-Koh N., Xu M., Feierbach B. A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection. PLoS Pathog. 2014, 10:e1004060.
12. Aulitzky W.E., Schulz T.F., Tilg H., Niederwieser D., Larcher K., Ostberg L., Scriba M., Martindale J., Stern A.C., Grass P., et al. Human monoclonal antibodies neutralizing cytomegalovirus (CMV) for prophylaxis of CMV disease: report of a phase I trial in bone marrow transplant recipients. J. Infect. Dis. 1991, 163:1344-1347.
13. Axelsson F., Adler S.P., Lamarre A., Ohlin M. Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines. Vaccine 2007, 26:41-46.
14. Axelsson F., Persson J., Moreau E., Cote M.H., Lamarre A., Ohlin M. Novel antibody specificities targeting glycoprotein B of cytomegalovirus identified by molecular library technology. N. Biotechnol. 2009, 25:429-436.
15. Azuma J., Kurimoto T., Tsuji S., Mochizuki N., Fujinaga S., Matsumoto Y., Masuho Y. Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J. Immunother. 1991, 10:278-285.
16. Baldanti F., Paolucci S., Campanini G., Sarasini A., Percivalle E., Revello M.G., Gerna G. Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Arch. Virol. 2006, 151:1225-1233.
17. Barrios Y., Knor S., Lantto J., Mach M., Ohlin M. Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol. Immunol. 2007, 44:680-690.
18. Barron M.A., Gao D., Springer K.L., Patterson J.A., Brunvand M.W., McSweeney P.A., Zeng C., Baron A.E., Weinberg A. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2009, 49:1777-1783.
19. Baryawno N., Rahbar A., Wolmer-Solberg N., Taher C., Odeberg J., Darabi A., Khan Z., Sveinbjornsson B., Fuskevag O.M., Segerstrom L., Nordenskjold M., Siesjo P., Kogner P., Johnsen J.I., Soderberg-Naucler C. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J. Clin. Invest. 2011, 121:4043-4055.
20. Beswick M., Pachnio A., Lauder S.N., Sweet C., Moss P.A. Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection. J. Virol. 2013, 87:779-789.
21. Bianchi E., Roncarati P., Hougrand O., Guerin-El Khourouj V., Boreux R., Kroonen J., Martin D., Robe P., Rogister B., Delvenne P., Deprez M. Human cytomegalovirus and primary intracranial tumors: frequency of tumor infection and lack of correlation with systemic immune anti-viral responses. Neuropathol. Appl. Neurobiol. 2015, 41:e29-e40.
22. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells [see comments]. N. Engl. J. Med. 1989, 320:1731-1735.
23. Boeckh M., Bowden R.A., Storer B., Chao N.J., Spielberger R., Tierney D.K., Gallez-Hawkins G., Cunningham T., Blume K.G., Levitt D., Zaia J.A. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2001, 7:343-351.
24. Boldicke T., Haase B., Bocher M., Lindenmaier W. Human monoclonal antibodies to cytomegalovirus. Characterization and recombinant expression of a glycoprotein-B-specific antibody. Eur. J. Biochem. 1995, 234:397-405.
25. Boppana S.B., Rivera L.B., Fowler K.B., Mach M., Britt W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med. 2001, 344:1366-1371.
26. Borucki M.J., Spritzler J., Asmuth D.M., Gnann J., Hirsch M.S., Nokta M., Aweeka F., Nadler P.I., Sattler F., Alston B., Nevin T.T., Owens S., Waterman K., Hubbard L., Caliendo A., Pollard R.B., Team A. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antivir. Res. 2004, 64:103-111.
27. Both L., Banyard A.C., van Dolleweerd C., Wright E., Ma J.K., Fooks A.R. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine 2013, 31:1553-1559.
28. Bradshaw P.A., Duran-Guarino M.R., Perkins S., Rowe J.I., Fernandez J., Fry K.E., Reyes G.R., Young L., Foung S.K. Localization of antigenic sites on human cytomegalovirus virion structural proteins encoded by UL48 and UL56. Virology 1994, 205:321-328.
29. Bratcher D.F., Bourne N., Bravo F.J., Schleiss M.R., Slaoui M., Myers M.G., Bernstein D.I. Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J. Infect. Dis. 1995, 172:944-950.
30. Bregenholt S., Haurum J. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin. Biol. Ther. 2004, 4:387-396.
31. Bregenholt S., Jensen A., Lantto J., Hyldig S., Haurum J.S. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. 2006, 12:2007-2015.
32. Britt W.J. Neutralizing antibodies detect a disulfidelinked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984, 135:369-378.
33. Britt W.J., Alford C.A. Cytomegalovirus. Fields Virology 1996, 2493-2523. Lippincott-Raven Publishers, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
34. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 1990, 64:1079-1085.
35. Britt W.J., Vugler L.G. Antiviral antibody responses in mothers and their newborn infants with clinical and subclinical congenital cytomegalovirus infections. J. Infect. Dis. 1990, 161:214-219.
36. Bron D., Delforge A., Lagneaux L., De Martynoff G., Bosmans E., Van der Auwera P., Snoeck R., Burny A., Stryckmans P. Production of human monoclonal IgG antibodies reacting with cytomegalovirus (CMV). J. Immunol. Methods 1990, 130:209-216.
37. Bukowski J.F., Warner J.F., Dennert G., Welsh R.M. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J. Exp. Med. 1985, 161:40.
38. Burkhardt C., Himmelein S., Britt W., Winkler T., Mach M. Glycoprotein N subtypes of human cytomegalovirus induce a strain-specific antibody response during natural infection. J. Gen. Virol. 2009, 90:1951-1961.
39. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
40. Carbone J., Sarmiento E., Palomo J., Fernandez-Yanez J., Munoz P., Bouza E., Rodriguez-Molina J., Lanio N., Fernandez-Cruz E. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Transplant. Proc. 2007, 39:2385-2388.
41. Carlsson F., Trilling M., Perez F., Ohlin M. A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus. J. Immunol. Methods 2012, 376:69-78.
42. Casali P., Inghirami G., Nakamura M., Davies T.F., Notkins A.L. Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV. Science 1986, 234:476-479.
43. Cekinovic D., Golemac M., Pugel E.P., Tomac J., Cicin-Sain L., Slavuljica I., Bradford R., Misch S., Winkler T.H., Mach M., Britt W.J., Jonjic S. Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J. Virol. 2008, 82:12172-12180.
44. Chen, X., Dennis, M., Feierbach, B.L., Fouts, A.E., Hotzel, I., Li, B., 2012. Antibody compositions and methods of use. WIPO, WO2012047732.
45. Cheung A.K., Gottlieb D.J., Plachter B., Pepperl-Klindworth S., Avdic S., Cunningham A.L., Abendroth A., Slobedman B. The role of the human cytomegalovirus UL111A gene in down-regulating CD4+ T-cell recognition of latently infected cells: implications for virus elimination during latency. Blood 2009, 114:4128-4137.
46. Cheung W.C., Beausoleil S.A., Zhang X., Sato S., Schieferl S.M., Wieler J.S., Beaudet J.G., Ramenani R.K., Popova L., Comb M.J., Rush J., Polakiewicz R.D. A proteomics approach for the identification and cloning of monoclonal antibodies from serum. Nat. Biotechnol. 2012, 30:447-452.
47. Cobbs C.S., Harkins L., Samanta M., Gillespie G.Y., Bharara S., King P.H., Nabors L.B., Cobbs C.G., Britt W.J. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002, 62:3347-3350.
48. Corrales-Aguilar E., Hoffmann K., Hengel H. CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol. 2014, 36:627-640.
49. Corrales-Aguilar E., Trilling M., Hunold K., Fiedler M., Le V.T., Reinhard H., Ehrhardt K., Merce-Maldonado E., Aliyev E., Zimmermann A., Johnson D.C., Hengel H. Human cytomegalovirus Fcgamma binding proteins gp34 and gp68 antagonize Fcgamma receptors I, II and III. PLoS Pathog. 2014, 10:e1004131.
50. Corrales-Aguilar E., Trilling M., Reinhard H., Merce-Maldonado E., Widera M., Schaal H., Zimmermann A., Mandelboim O., Hengel H. A novel assay for detecting virus-specific antibodies triggering activation of Fcgamma receptors. J. Immunol. Methods 2013, 387:21-35.
51. Coughlin M.M., Prabhakar B.S. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev. Med. Virol. 2012, 22:2-17.
52. Couzi L., Pitard V., Sicard X., Garrigue I., Hawchar O., Merville P., Moreau J.F., Dechanet-Merville J. Antibody-dependent anti-cytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood 2012, 119:1418-1427.
53. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 2009, 22:76-98.
54. Cui X., Meza B.P., Adler S.P., McVoy M.A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008, 26:5760-5766.
55. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 2006, 281:23514-23524.
56. de Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., Goudsmit J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu. Rev. Med. 2007, 58:359-368.
57. DeKosky B.J., Ippolito G.C., Deschner R.P., Lavinder J.J., Wine Y., Rawlings B.M., Varadarajan N., Giesecke C., Dorner T., Andrews S.F., Wilson P.C., Hunicke-Smith S.P., Willson C.G., Ellington A.D., Georgiou G. High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. Nat. Biotechnol. 2013, 31:166-169.
58. Deng, R., Emu, B., 2014. Methods for inhibiting viral infection in transplant patients. WIPO, WO2014099908.
59. DesJardin J.A., Snydman D.R. Antiviral immunotherapy: a review of current status. BioDrugs 1998, 9:487-507.
60. Drobyski W.R., Gottlieb M., Carrigan D., Ostberg L., Grebenau M., Schran H., Magid P., Ehrlich P., Nadler P.I., Ash R.C. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991, 51:1190-1196.
61. Dunkel E.C., Siegel M.L., Brooks J., Tolpin M.D., Magid P., Freitas D., Pavan-Langston D. MSL-109 therapy of human cytomegalovirus-induced chorioretinitis in the rabbit. Antivir. Res. 1991, 15:121.
62. Dunn W., Chou C., Li H., Hai R., Patterson D., Stolc V., Zhu H., Liu F. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14223-14228.
63. Dzabic M., Rahbar A., Yaiw K.C., Naghibi M., Religa P., Fellstrom B., Larsson E., Soderberg-Naucler C. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin. Infect. Dis. 2011, 53:969-976.
64. Ehrlich P.H., Harfeldt K.E., Justice J.C., Moustafa Z.A., Ostberg L. Rhesus monkey responses to multiple injections of human monoclonal antibodies. Hybridoma 1987, 6:151-160.
65. Ehrlich P.H., Moustafa Z.A., Justice J.C., Harfeldt K.E., Ostberg L. Further characterization of the fate of human monoclonal antibodies in rhesus monkeys. Hybridoma 1988, 7:385-395.
66. Ehrlich P.H., Ostberg L. Characterization of human anti-cytomegalovirus monoclonal antibodies. Therapeutic Monoclonal Antibodies 1990, 209-222. Stockton Press, New York. C.A.K. Borrebaeck, J.W. Larrick (Eds.).
67. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol. 2003, 77:5226-5240.
68. Emanuel D., Gold J., Colacino J., Lopez C., Hammerling U. A human monoclonal antibody to cytomegalovirus (CMV). J. Immunol. 1984, 133:2202-2205.
69. European Medicines Agency Public Summary of Opinion on Orphan Designation. EMA/COMP/29801/2014 2014.
70. Flinsenberg T.W., Compeer E.B., Koning D., Klein M., Amelung F.J., van Baarle D., Boelens J.J., Boes M. Fcgamma receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood 2012, 120:5163-5172.
71. Foung S.K., Perkins S. Electric field-induced cell fusion and human monoclonal antibodies. J. Immunol. Methods 1989, 116:117-122.
72. Foung S.K., Perkins S., Bradshaw P., Rowe J., Rabin L.B., Reyes G.R., Lennette E.T. Human monoclonal antibodies to human cytomegalovirus. J. Infect. Dis. 1989, 159:436-443.
73. Fouts A.E., Chan P., Stephan J.P., Vandlen R., Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 2012, 86:7444-7447.
74. Fouts A.E., Comps-Agrar L., Stengel K.F., Ellerman D., Schoeffler A.J., Warming S., Eaton D.L., Feierbach B. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:8209-8214.
75. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 1992, 326:663-667.
76. Freed D.C., Tang Q., Tang A., Li F., He X., Huang Z., Meng W., Xia L., Finnefrock A.C., Durr E., Espeseth A.S., Casimiro D.R., Zhang N., Shiver J.W., Wang D., An Z., Fu T.M. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E4997-E5005.
77. Frey G., Peng H., Rits-Volloch S., Morelli M., Cheng Y., Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3739-3744.
78. Funaro A., Gribaudo G., Luganini A., Ortolan E., Lo Buono N., Vicenzi E., Cassetta L., Landolfo S., Buick R., Falciola L., Murphy M., Garotta G., Malavasi F. Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells. BMC Biotechnol. 2008, 8:85.
79. Furebring C., Speckner A., Mach M., Sandlie I., Norderhaug L., Borrebaeck C.A., Turesson H., Ohlin M. Antibody-mediated neutralization of cytomegalovirus: modulation of efficacy induced through the IgG constant region. Mol. Immunol. 2002, 38:833-840.
80. Gardner T.J., Bolovan-Fritts C., Teng M.W., Redmann V., Kraus T.A., Sperling R., Moran T., Britt W., Weinberger L.S., Tortorella D. Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies. Clin. Vaccine Immunol. 2013, 20:540-550.
81. Geder K.M., Lausch R., O'Neill F., Rapp F. Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science 1976, 192:1134-1137.
82. Georgiou G., Ippolito G.C., Beausang J., Busse C.E., Wardemann H., Quake S.R. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat. Biotechnol. 2014, 32:158-168.
83. Gerna G., Sarasini A., Patrone M., Percivalle E., Fiorina L., Campanini G., Gallina A., Baldanti F., Revello M.G. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol. 2008, 89:853-865.
84. Gicklhorn D., Eickmann M., Meyer G., Ohlin M., Radsak K. Differential effects of glycoprotein B epitope-specific antibodies on human cytomegalovirus-induced cell-cell fusion. J. Gen. Virol. 2003, 84:1859-1862.
85. Gilpin A.M., Holbrook J.T., Jabs D.A., Meinert C.L. Data and safety monitoring board deliberations resulting in the early termination of the monoclonal antibody cytomegalovirus retinitis trial. Control. Clin. Trials 2003, 24:92-98. Studies-of-Ocular-Complications-of-Aids-Research-Group.
86. Giugni T.D., Söderberg C., Ham D.J., Bautista R., Hedlund K.-O., Möller E., Zaia J.A. Neutralization of human cytomegalovirus by human CD13 specific antibodies. J. Infect. Dis. 1996, 173:1062-1071.
87. Gkrania-Klotsas E., Langenberg C., Sharp S.J., Luben R., Khaw K.T., Wareham N.J. Higher immunoglobulin G antibody levels against cytomegalovirus are associated with incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J. Infect. Dis. 2012, 206:1897-1903.
88. Gonczol E., deTaisne C., Hirka G., Berencsi K., Lin W.C., Paoletti E., Plotkin S. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 1991, 9:631-637.
89. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., Oyer P.E., Stinson E.B., Shumway N.E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J. Am. Med. Assoc. 1989, 261:3561-3566.
90. Gretch D.R., Kari B., Rasmussen L., Gehrz R.C., Stinski M.F. Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus. J. Virol. 1988, 62:875-881.
91. Griffiths P.D., Stanton A., McCarrell E., Smith C., Osman M., Harber M., Davenport A., Jones G., Wheeler D.C., O'Beirne J., Thorburn D., Patch D., Atkinson C.E., Pichon S., Sweny P., Lanzman M., Woodford E., Rothwell E., Old N., Kinyanjui R., Haque T., Atabani S., Luck S., Prideaux S., Milne R.S., Emery V.C., Burroughs A.K. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
92. Gustafsson B., Jondal M., Sundqvist V.A. SPAM-8, a mouse-human heteromyeloma fusion partner in the production of human monoclonal antibodies. Establishment of a human monoclonal antibody against cytomegalovirus. Hum. Antib. Hybrid. 1991, 2:26-32.
93. Hadaczek P., Ozawa T., Soroceanu L., Yoshida Y., Matlaf L., Singer E., Fiallos E., James C.D., Cobbs C.S. Cidofovir: a novel antitumor agent for glioblastoma. Clin. Cancer Res. 2013, 19:6473-6483.
94. Hahn G., Revello M.G., Patrone M., Percivalle E., Campanini G., Sarasini A., Wagner M., Gallina A., Milanesi G., Koszinowski U., Baldanti F., Gerna G. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 2004, 78:10023-10033.
95. Hamilton A.A., Manuel D.M., Grundy J.E., Turner A.J., King S.I., Adair J.R., White P., Carr F.J., Harris W.J. A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections. J. Infect. Dis. 1997, 176:59-68.
96. Hanes J., Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4937-4942.
97. Hanley P.J., Bollard C.M. Controlling cytomegalovirus: helping the immune system take the lead. Viruses 2014, 6:2242-2258.
98. Hannah B.P., Cairns T.M., Bender F.C., Whitbeck J.C., Lou H., Eisenberg R.J., Cohen G.H. Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J. Virol. 2009, 83:6825-6836.
99. Harkins L., Volk A.L., Samanta M., Mikolaenko I., Britt W.J., Bland K.I., Cobbs C.S. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 2002, 360:1557-1563.
100. Harkins L.E., Matlaf L.A., Soroceanu L., Klemm K., Britt W.J., Wang W., Bland K.I., Cobbs C.S. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 2010, 1:8.
101. Helantera I., Koskinen P., Finne P., Loginov R., Kyllonen L., Salmela K., Gronhagen-Riska C., Lautenschlager I. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl. Int. 2006, 19:893-900.
102. Helantera I., Loginov R., Lautenschlager I., Helantera I., Koskinen P., Tornroth T., Gronhagen-Riska C. The role of cytomegalovirus infection in chronic allograft nephropathy. Transplantation 2005, 79:379.
103. Heldwein E.E., Krummenacher C. Entry of herpesviruses into mammalian cells. Cell. Mol. Life Sci. 2008, 65:1653-1668.
104. Heldwein E.E., Lou H., Bender F.C., Cohen G.H., Eisenberg R.J., Harrison S.C. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006, 313:217-220.
105. Hjelmesaeth J., Sagedal S., Hartmann A., Rollag H., Egeland T., Hagen M., Nordal K.P., Jenssen T. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004, 47:1550-1556.
106. Hsiung G.D., Bia F.J., Fong C.K. Viruses of guinea pigs: considerations for biomedical research. Microbiol. Rev. 1980, 44:468-490.
107. Huang J., Doria-Rose N.A., Longo N.S., Laub L., Lin C.L., Turk E., Kang B.H., Migueles S.A., Bailer R.T., Mascola J.R., Connors M. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 2013, 8:1907-1915.
108. Huang J., Kang B.H., Pancera M., Lee J.H., Tong T., Feng Y., Georgiev I.S., Chuang G.Y., Druz A., Doria-Rose N.A., Laub L., Sliepen K., van Gils M.J., de la Pena A.T., Derking R., Klasse P.J., Migueles S.A., Bailer R.T., Alam M., Pugach P., Haynes B.F., Wyatt R.T., Sanders R.W., Binley J.M., Ward A.B., Mascola J.R., Kwong P.D., Connors M. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
109. Huber M.T., Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J. Virol. 1998, 72:8191-8197.
110. HUMABS BioMed Pipeline 2014, http://www.humabs.com/index.php/science-and-technology/pipeline.
111. Humphreys I.R., de Trez C., Kinkade A., Benedict C.A., Croft M., Ware C.F. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J. Exp. Med. 2007, 204:1217-1225.
112. Hwang W.Y., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10.
113. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321:522-525.
114. Jonjic S., Mutter W., Weiland F., Reddehase M.J., Koszinowski U.H. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J. Exp. Med. 1989, 169:1199-1212.
115. Kaariainen L., Klemola E., Paloheimo J. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br. Med. J. 1966, 5498:1270-1272.
116. Kabanova A., Perez L., Lilleri D., Marcandalli J., Agatic G., Becattini S., Preite S., Fuschillo D., Percivalle E., Sallusto F., Gerna G., Corti D., Lanzavecchia A. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:17965-17970.
117. Kalil R.S., Hudson S.L., Gaston R.S. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?. Am. J. Transplant. 2003, 3:79-81.
118. Kari B., Gehrz R. Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II. J. Gen. Virol. 1993, 74:255-264.
119. Karpas A., Dremucheva A., Czepulkowski B.H. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1799-1804.
120. Kauvar L.M., Liu K., Park M., DeChene N., Stephenson R., Tenorio E., Ellsworth S.L., Tabata T., Petitt M., Tsuge M., Fang-Hoover J., Adler S.P., Cui X., McVoy M.A., Pereira L. A high affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob. Agents Chemother. 2015, 59:1558-1568.
121. Kaye J.F., Gompels U.A., Minson A.C. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product. J. Gen. Virol. 1992, 73:2693-2698.
122. Klemola E., Kääriäinen L. Cytomgelovirus as a possible cause of a disease resembling infectious mononucleosis. Br. Med. J. 1965, 2:1099-1102.
123. Kniess N., Mach M., Fay J., Britt W.J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 1991, 65:138-146.
124. Kocks C., Rajewsky K. Stepwise intraclonal maturation of antibody affinity through somatic hypermutation. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:8206-8210.
125. Kohler G., Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 1976, 6:511-519.
126. Krampe K., Briem-Richter A., Fischer L., Nashan B., Ganschow R. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr. Transplant. 2010, 14:67-71.
127. Kropff B., Burkhardt C., Schott J., Nentwich J., Fisch T., Britt W., Mach M. Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog. 2012, 8:e1002999.
128. Kropff B., Landini M.P., Mach M. An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus. J. Med. Virol. 1993, 39:187-195.
129. Kubota T., Niwa R., Satoh M., Akinaga S., Shitara K., Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009, 100:1566-1572.
130. Kuparinen T., Marttila S., Jylhava J., Tserel L., Peterson P., Jylha M., Hervonen A., Hurme M. Cytomegalovirus (CMV)-dependent and -independent changes in the aging of the human immune system: a transcriptomic analysis. Exp. Gerontol. 2013, 48:305-312.
131. Kwakkenbos M.J., Diehl S.A., Yasuda E., Bakker A.Q., van Geelen C.M., Lukens M.V., van Bleek G.M., Widjojoatmodjo M.N., Bogers W.M., Mei H., Radbruch A., Scheeren F.A., Spits H., Beaumont T. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 2010, 16:123-128.
132. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
133. Lakeman F., Blevins C., Whitley R., Tolpin M.D. In vitro neutralization of cytomegalovirus strain by a human monoclonal antibody, MSL-109. Antivir. Res. 1991, 15:77.
134. Lameris R., de Bruin R.C., Schneiders F.L., van Bergen En Henegouwen P.M., Verheul H.M., de Gruijl T.D., van der Vliet H.J. Bispecific antibody platforms for cancer immunotherapy. Crit. Rev. Oncol. Hematol. 2014, 92:153-165.
135. Lantto J., Fletcher J.M., Ohlin M. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus. Virology 2003, 305:201-209.
136. Lantto J., Haahr Hansen M., Rasmussen S.K., Steinaa L., Poulsen T.R., Duggan J., Dennis M., Naylor I., Easterbrook L., Bregenholt S., Haurum J., Jensen A. Capturing the natural diversity of the human antibody response against vaccinia virus. J. Virol. 2011, 85:1820-1833.
137. Lantto J., Lindroth Y., Ohlin M. Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus. Eur. J. Immunol. 2002, 32:1659-1669.
138. Li B., Fouts A.E., Stengel K., Luan P., Dillon M., Liang W.C., Feierbach B., Kelley R.F., Hotzel I. In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation. MAbs 2014, 6:437-445.
139. Lilleri D., Kabanova A., Lanzavecchia A., Gerna G. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J. Clin. Immunol. 2012, 32:1324-1331.
140. Lilleri D., Kabanova A., Revello M.G., Percivalle E., Sarasini A., Genini E., Sallusto F., Lanzavecchia A., Corti D., Gerna G. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLOS ONE 2013, 8:e59863.
141. Ljungman P., Perez-Bercoff L., Jonsson J., Avetisyan G., Sparrelid E., Aschan J., Barkholt L., Larsson K., Winiarski J., Yun Z., Ringden O. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
142. Lonnqvist B., Ringden O., Wahren B., Gahrton G., Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984, 38:465-468.
143. Lum L.G., Ramesh M., Thakur A., Mitra S., Deol A., Uberti J.P., Pellett P.E. Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 x anti-CMV bispecific antibody. Biol. Blood Marrow Transplant. 2012, 18:1012-1022.
144. Macagno A., Bernasconi N.L., Vanzetta F., Dander E., Sarasini A., Revello M.G., Gerna G., Sallusto F., Lanzavecchia A. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 2010, 84:1005-1013.
145. Manley K., Anderson J., Yang F., Szustakowski J., Oakeley E.J., Compton T., Feire A.L. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 2011, 10:197-209.
146. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
147. Mason G.M., Jackson S., Okecha G., Poole E., Sissons J.G., Sinclair J., Wills M.R. Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4(+) T cells. PLoS Pathog. 2013, 9:e1003635.
148. Masuho Y., Matsumoto Y., Sugano T., Fujinaga S., Minamishima Y. Human monoclonal antibodies neutralizing human cytomegalovirus. J. Gen. Virol. 1987, 68:1457-1461.
149. Matsumoto Y., Sugano T., Miyamoto C., Masuho Y. Generation of hybridomas producing human monoclonal antibodies against human cytomegalovirus. Biochem. Biophys. Res. Commun. 1986, 137:273-280.
150. McCafferty J., Griffiths A.D., Winter G., Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348:552-554.
151. McCutcheon K.M., Gray J., Chen N.Y., Liu K., Park M., Ellsworth S., Tripp R.A., Tompkins S.M., Johnson S.K., Samet S., Pereira L., Kauvar L.M. Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs 2014, 6:460-473.
152. McLean G.R., Olsen O.A., Watt I.N., Rathanaswami P., Leslie K.B., Babcook J.S., Schrader J.W. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J. Immunol. 2005, 174:4768-4778.
153. Meijer P.J., Andersen P.S., Haahr Hansen M., Steinaa L., Jensen A., Lantto J., Oleksiewicz M.B., Tengbjerg K., Poulsen T.R., Coljee V.W., Bregenholt S., Haurum J.S., Nielsen L.S. Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. J. Mol. Biol. 2006, 358:764-772.
154. Meyer H., Masuho Y., Mach M. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J. Gen. Virol. 1990, 71:2443-2450.
155. Meyer H., Sundqvist V.A., Pereira L., Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J. Gen. Virol. 1992, 73:2375-2383.
156. Meyer-Konig U., Haberland M., von Laer D., Haller O., Hufert F.T. Intragenic variability of human cytomegalovirus glycoprotein B in clinical strains. J. Infect. Dis. 1998, 177:1162-1169.
157. Michaelsen T.E., Aase A., Norderhaug L., Sandlie I. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol. Immunol. 1992, 29:319-326.
158. Mocarski E.S., Shenk T., Pass R. Cytomegaloviruses. Fields Virology 2007, 2701-2772. Lippincott Williams and Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
159. Morrison S.L., Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6851-6855.
160. Murphy E., Yu D., Grimwood J., Schmutz J., Dickson M., Jarvis M.A., Hahn G., Nelson J.A., Myers R.M., Shenk T.E. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14976-14981.
161. Nair S.K., De Leon G., Boczkowski D., Schmittling R., Xie W., Staats J., Liu R., Johnson L.A., Weinhold K., Archer G.E., Sampson J.H., Mitchell D.A. Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. Clin. Cancer Res. 2014, 20:2684-2694.
162. Nair S.K., Sampson J.H., Mitchell D.A. Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology 2014, 3:e29289.
163. Navarro D., Lennette E., Tugizov S., Pereira L. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J. Med. Virol. 1997, 52:451-459.
164. Nejatollahi F., Hodgetts S.J., Vallely P.J., Burnie J.P. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol. Med. Microbiol. 2002, 34:237-244.
165. Newkirk M.M., Gram H., Heinrich G.F., Ostberg L., Capra J.D., Wasserman R.L. Complete protein sequences of the variable regions of the cloned heavy and light chains of a human anti-cytomegalovirus antibody reveal a striking similarity to human monoclonal rheumatoid factors of the Wa idiotypic family. J. Clin. Invest. 1988, 81:1511-1518.
166. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 2005, 353:1350-1362.
167. Nixon A.E., Sexton D.J., Ladner R.C. Drugs derived from phage display: from candidate identification to clinical practice. MAbs 2014, 6:73-85.
168. Norderhaug L., Brekke O.H., Bremnes B., Sandin R., Aase A., Michaelsen T.E., Sandlie I. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge. Eur. J. Immunol. 1991, 21:2379-2384.
169. Noriega V., Redmann V., Gardner T., Tortorella D. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 2012, 54:140-151.
170. Ober R.J., Radu C.G., Ghetie V., Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 2001, 13:1551-1559.
171. Ohizumi Y., Suzuki H., Matsumoto Y., Masuho Y., Numazaki Y. Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55. J. Gen. Virol. 1992, 73:2705-2707.
172. Ohlin M. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?. Mol. Immunol. 2014, 60:95-102.
173. Ohlin M., Owman H., Mach M., Borrebaeck C.A. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol. Immunol. 1996, 33:47-56.
174. Ohlin M., Owman H., Rioux J.D., Newkirk M.M., Borrebaeck C.A. Restricted variable region gene usage and possible rheumatoid factor relationship among human monoclonal antibodies specific for the AD-1 epitope on cytomegalovirus glycoprotein B. Mol. Immunol. 1994, 31:983-991.
175. Ohlin M., Plachter B., Sundqvist V.A., Steenbakkers P.G., Middeldorp J.M., Borrebaeck C.A. Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus. Clin. Diagn. Lab. Immunol. 1995, 2:325-329.
176. Ohlin M., Silvestri M., Sundqvist V.A., Borrebaeck C.A. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin. Diagn. Lab. Immunol. 1997, 4:107-111.
177. Ohlin M., Sundqvist V.A., Gilljam G., Ruden U., Gombert F.O., Wahren B., Borrebaeck C.A. Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin. Exp. Immunol. 1991, 84:508-514.
178. Ohlin M., Sundqvist V.A., Mach M., Wahren B., Borrebaeck C.A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 1993, 67:703-710.
179. Olsen, O., 2009. Compositions and methods for the therapy and diagnosis of cytomegalovirus. WIPO, WO2009114560.
180. Olsson L., Kaplan H.S. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:5429-5431.
181. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., Corey L., Hill J., Davis E., Flanigan C., Cloud G. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 2009, 360:1191-1199.
182. Pawelec G. Immunosenenescence: role of cytomegalovirus. Exp. Gerontol. 2014, 54:1-5.
183. Pereira L., Hoffman M., Gallo D., Cremer N. Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants. Infect. Immun. 1982, 36:924-932.
184. Pereira L., Maidji E., McDonagh S., Tabata T. Insights into viral transmission at the uterine-placental interface. Trends Microbiol. 2005, 13:164-174.
185. Pini A., Spreafico A., Botti R., Neri D., Neri P. Hierarchical affinity maturation of a phage library derived antibody for the selective removal of cytomegalovirus from plasma. J. Immunol. Methods 1997, 206:171-182.
186. Planitzer C.B., Saemann M.D., Gajek H., Farcet M.R., Kreil T.R. Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations. Transplantation 2011, 92:267-270.
187. Potena L., Valantine H.A. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr. Opin. Infect. Dis. 2007, 20:425-431.
188. Potzsch S., Spindler N., Wiegers A.K., Fisch T., Rucker P., Sticht H., Grieb N., Baroti T., Weisel F., Stamminger T., Martin-Parras L., Mach M., Winkler T.H. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011, 7:e1002172.
189. Poulsen T.R., Meijer P.J., Jensen A., Nielsen L.S., Andersen P.S. Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J. Immunol. 2007, 179:3841-3850.
190. Prins R.M., Cloughesy T.F., Liau L.M. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N. Engl. J. Med. 2008, 359:539-541.
191. Qadri I., Navarro D., Paz P., Pereira L. Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J. Gen. Virol. 1992, 73:2913-2921.
192. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., Fausther-Bovendo H., Wei H., Aviles J., Hiatt E., Johnson A., Morton J., Swope K., Bohorov O., Bohorova N., Goodman C., Kim D., Pauly M.H., Velasco J., Pettitt J., Olinger G.G., Whaley K., Xu B., Strong J.E., Zeitlin L., Kobinger G.P. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
193. Raanani P., Gafter-Gvili A., Paul M., Ben-Bassat I., Leibovici L., Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J. Clin. Oncol. 2009, 27:770-781.
194. Rahbar A., Orrego A., Peredo I., Dzabic M., Wolmer-Solberg N., Straat K., Stragliotto G., Soderberg-Naucler C. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J. Clin. Virol. 2013, 57:36-42.
195. Rahbar A., Peredo I., Wolmer-Solberg N., Taher C., Dzabic M., Xu X., Skarman P., Fornara O., Tammik C., Yaiw K., Wilhelmi V., Alice Assinger A., Giuseppe Stragliotto G., Söderberg-Naucler C. Disccordant humoral and cellular immune responses to cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV. Oncoimmunology 2015, (in press). 10.4161/2162402X.2014.982391.
196. Rasmussen L.E., Nelson R.M., Kelsall D.C., Merigan T.C. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:876-880.
197. Razonable R.R., Paya C.V. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003, 10:60-65.
198. Reeves M.B., Breidenstein A., Compton T. Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:588-593.
199. Reeves M.B., MacAry P.A., Lehner P.J., Sissons J.G., Sinclair J.H. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4140-4145.
200. Reinhard H., Le V.T., Ohlin M., Hengel H., Trilling M. Exploitation of herpesviral transactivation allows quantitative reporter gene-based assessment of virus entry and neutralization. PLoS ONE 2011, 6:e14532.
201. Reinke P., Fietze E., Ode-Hakim S., Prosch S., Lippert J., Ewert R., Volk H.D. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994, 344:1737-1738.
202. Revello M.G., Zavattoni M., Furione M., Lilleri D., Gorini G., Gerna G. Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections. J. Infect. Dis. 2002, 186:553-557.
203. Rubin R.H. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J. Am. Med. Assoc. 1989, 261:3607-3609.
204. Samanta M., Harkins L., Klemm K., Britt W.J., Cobbs C.S. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J. Urol. 2003, 170:998-1002.
205. Sato, S., Beausoleil, S.A., Cheung, W.C., Polakiewicz, R.D., 2013. Anti-human cytomegalovirus antibodies and use thereof. WIPO, WO2013/165982.
206. Sato S., Beausoleil S.A., Popova L., Beaudet J.G., Ramenani R.K., Zhang X., Wieler J.S., Schieferl S.M., Cheung W.C., Polakiewicz R.D. Proteomics-directed cloning of circulating antiviral human monoclonal antibodies. Nat. Biotechnol. 2012, 30:1039-1043.
207. Schleiss M.R. Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin. Dev. Immunol. 2013, 2013:501801.
208. Schoppel K., Hassfurther E., Britt W., Ohlin M., Borrebaeck C.A., Mach M. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 1996, 216:133-145.
209. Schoppel K., Schmidt C., Einsele H., Hebart H., Mach M. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 1998, 178:1233-1243.
210. Schrader J.W., McLean G.R. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies. Immunol. Lett. 2007, 112:58-60.
211. Schuessler A., Walker D.G., Khanna R. Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment. Oncoimmunology 2014, 3:e29381.
212. Seckert C.K., Renzaho A., Reddehase M.J., Grzimek N.K. Hematopoietic stem cell transplantation with latently infected donors does not transmit virus to immunocompromised recipients in the murine model of cytomegalovirus infection. Med. Microbiol. Immunol. 2008, 197:251-259.
213. Shawler D.L., Bartholomew R.M., Smith L.M., Dillman R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 135:1530-1535.
214. Shellam G.R., Allan J.E., Papadimitriou J.M., Bancroft G.J. Increased susceptibility to cytomegalovirus infection in beige mutant mice. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:5104-5108.
215. Shen S., Wang S., Britt W.J., Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine 2007, 25:3319-3327.
216. Shimamura M., Mach M., Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J. Virol. 2006, 80:4591-4600.
217. Silvestri M., Sundqvist V.A., Ruden U., Wahren B. Characterization of a major antigenic region on gp55 of human cytomegalovirus. J. Gen. Virol. 1991, 72:3017-3023.
218. Simanek A.M., Dowd J.B., Pawelec G., Melzer D., Dutta A., Aiello A.E. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS ONE 2011, 6:e16103.
219. Sinclair J., Sissons P. Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 2006, 87:1763-1779.
220. Soderberg C., Giugni T.D., Zaia J.A., Larsson S., Wahlberg J.M., Moller E. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J. Virol. 1993, 67:6576-6585.
221. Soderberg-Naucler C. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit. Rev. Immunol. 2006, 26:231-264.
222. Soderberg-Naucler C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997, 91:119-126.
223. Soderberg-Naucler C., Rahbar A., Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N. Engl. J. Med. 2013, 369:985-986.
224. Soderberg-Naucler C., Streblow D.N., Fish K.N., Allan-Yorke J., Smith P.P., Nelson J.A. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J. Virol. 2001, 75:7543-7554.
225. Solana R., Tarazona R., Aiello A.E., Akbar A.N., Appay V., Beswick M., Bosch J.A., Campos C., Cantisan S., Cicin-Sain L., Derhovanessian E., Ferrando-Martinez S., Frasca D., Fulop T., Govind S., Grubeck-Loebenstein B., Hill A., Hurme M., Kern F., Larbi A., Lopez-Botet M., Maier A.B., McElhaney J.E., Moss P., Naumova E., Nikolich-Zugich J., Pera A., Rector J.L., Riddell N., Sanchez-Correa B., Sansoni P., Sauce D., van Lier R., Wang G.C., Wills M.R., Zielinski M., Pawelec G. CMV and immunosenescence: from basics to clinics. Immun. Ageing 2012, 9:23.
226. Soroceanu L., Cobbs C.S. Is HCMV a tumor promoter?. Virus Res. 2011, 157:193-203.
227. Spaete R.R., Gehrz R.C., Landini M.P. Human cytomegalovirus structural proteins. J. Gen. Virol. 1994, 75(Pt 12):3287-3308.
228. Spear G.T., Lurain N.S., Parker C.J., Ghassemi M., Payne G.H., Saifuddin M. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J. Immunol. 1995, 155:4376-4381.
229. Speckner A., Glykofrydes D., Ohlin M., Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 1999, 80:2183-2191.
230. Speckner A., Kropff B., Knor S., Mach M. The antigenic domain 1 of human cytomegalovirus glycoprotein B contains an intramolecular disulphide bond. J. Gen. Virol. 2000, 81:2659-2663.
231. Spindler N., Diestel U., Stump J.D., Wiegers A.K., Winkler T.H., Sticht H., Mach M., Muller Y.A. Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS Pathog. 2014, 10:e1004377.
232. Spindler N., Rucker P., Potzsch S., Diestel U., Sticht H., Martin-Parras L., Winkler T.H., Mach M. Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus. J. Virol. 2013, 87:8927-8939.
233. Stagno S., Pass R.F., Cloud G., Britt W.J., Henderson R.E., Walton P.D., Veren D.A., Page F., Alford C.A. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. J. Am. Med. Assoc. 1986, 256:1904-1908.
234. Steinitz M., Klein G., Koskimies S., Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977, 269:420-422.
235. Stern-Ginossar N., Weisburd B., Michalski A., Le V.T., Hein M.Y., Huang S.X., Ma M., Shen B., Qian S.B., Hengel H., Mann M., Ingolia N.T., Weissman J.S. Decoding human cytomegalovirus. Science 2012, 338:1088-1093.
236. Vaccines for the 21st Century: A Tool for Decisionmaking 2001, National Academy Press, Washington, DC. K.R. Stratton, J.S. Durch, R.S. Lawrence (Eds.).
237. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 2005, 202:673-685.
238. Taher C., de Boniface J., Mohammad A.A., Religa P., Hartman J., Yaiw K.C., Frisell J., Rahbar A., Soderberg-Naucler C. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLOS ONE 2013, 8:e56795.
239. Taher C., Frisk G., Fuentes S., Religa P., Costa H., Assinger A., Vetvik K., Rashid-Bukholm I., Yaiw K.-C., Ekström Smedby K., Bäcklund M., Söderberg-Naucler C., Rahbar A. High prevalence of human cytomegalovirus in brain metastases of patients with primary breast and colorectal cancer. Transl. Oncol. 2015, 7:732-740.
240. Takekoshi M., Maeda F., Tachibana H., Inoko H., Kato S., Takakura I., Kenjyo T., Hiraga S., Ogawa Y., Horiki T., Ihara S. Human monoclonal anti-HCMV neutralizing antibody from phage display libraries. J. Virol. Methods 1998, 74:89-98.
241. Tatebayashi M., Neyts J., Besen G., Flores-Aguilar M., Smith I.L., Wiley C.A., Spector S.A., Bergeron-Lynn G., Maudgal P.C., De Clercq E., et al. Absence of infectious retinitis after injection of human cytomegalovirus into rabbit eyes. J. Infect. Dis. 1995, 171:782-787.
242. Theraclone Sciences Inc. Theraclone Sciences Announces Positive Top-Line Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Cytomegalovirus Infection 2013, http://www.theraclone-sciences.com/pdf/Theraclone_Press_Release-4-2-13.pdf.
243. Thomson C.A., Bryson S., McLean G.R., Creagh A.L., Pai E.F., Schrader J.W. Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J. 2008, 27:2592-2602.
244. Tomiyama T., Masuho Y. Antiviral activities of a human monoclonal antibody against human cytomegalovirus. Adv. Exp. Med. Biol. 1990, 278:105-113.
245. Tomiyama T., Matsumoto Y., Sugano T., Fujinaga S., Masuho Y. Preparation of human monoclonal antibodies against a cytomegalovirus glycoprotein complex of 130 and 55kDa. J. Immunol. Methods 1990, 131:249-255.
246. Traggiai E., Becker S., Subbarao K., Kolesnikova L., Uematsu Y., Gismondo M.R., Murphy B.R., Rappuoli R., Lanzavecchia A. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 2004, 10:871-875.
247. Trellis Bioscience Infectious Disease (viruses) 2014, http://www.trellisbio.com/disease-areas/viruses.html.
248. Tu W., Potena L., Stepick-Biek P., Liu L., Dionis K.Y., Luikart H., Fearon W.F., Holmes T.H., Chin C., Cooke J.P., Valantine H.A., Mocarski E.S., Lewis D.B. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006, 114:1608-1615.
249. Urban M., Britt W., Mach M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 1992, 66:1303-1311.
250. Utz U., Britt W., Vugler L., Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J. Virol. 1989, 63:1995-2001.
251. Valantine H.A., Gao S.Z., Menon S.G., Renlund D.G., Hunt S.A., Oyer P., Stinson E.B., Brown B.W., Merigan T.C., Schroeder J.S. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999, 100:61-66.
252. van den Berg A.P., Klompmaker I.J., Haagsma E.B., Peeters P.M., Meerman L., Verwer R., The T.H., Slooff M.J. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin. Transplant. 1996, 10:224-231.
253. Vanarsdall A.L., Johnson D.C. Human cytomegalovirus entry into cells. Curr. Opin. Virol. 2012, 2:37-42.
254. Varnum S.M., Streblow D.N., Monroe M.E., Smith P., Auberry K.J., Pasa-Tolic L., Wang D., Camp D.G., Rodland K., Wiley S., Britt W., Shenk T., Smith R.D., Nelson J.A. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J. Virol. 2004, 78:10960-10966.
255. Vincent K.J., Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol. J. 2012, 7:1444-1450.
256. Wagner B., Kropff B., Kalbacher H., Britt W., Sundqvist V.A., Ostberg L., Mach M. A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J. Virol. 1992, 66:5290-5297.
257. Wang D., Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 2005, 79:10330-10338.
258. Wang D., Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18153-18158.
259. Weekes M.P., Tomasec P., Huttlin E.L., Fielding C.A., Nusinow D., Stanton R.J., Wang E.C., Aicheler R., Murrell I., Wilkinson G.W., Lehner P.J., Gygi S.P. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 2014, 157:1460-1472.
260. Weigert C. Ueber eine methode zur farbung elasticher farsen. Zbl. allg. Path. path. Anat. 1898, 9:289-292.
261. Wiegers A.K., Sticht H., Winkler T.H., Britt W., Mach M. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus. J. Virol. 2015, 89:361-372.
262. Wille P.T., Wisner T.W., Ryckman B., Johnson D.C. Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. MBio 2013, 4:e00332-e00413.
263. Williamson R.A., Burioni R., Sanna P.P., Partridge L.J., Barbas C.F., Burton D.R. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4141-4145.
264. Wolmer-Solberg N., Baryawno N., Rahbar A., Fuchs D., Odeberg J., Taher C., Wilhelmi V., Milosevic J., Mohammad A.A., Martinsson T., Sveinbjornsson B., Johnsen J.I., Kogner P., Soderberg-Naucler C. Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target?. Int. J. Cancer 2013, 133:2351-2361.
265. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., Zheng N.Y., Mays I., Garman L., Helms C., James J., Air G.M., Capra J.D., Ahmed R., Wilson P.C. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
266. Wu Z., Sinzger C., Frascaroli G., Reichel J., Bayer C., Wang L., Schirmbeck R., Mertens T. Human cytomegalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors dependent on humoral antiviral immunity. J. Virol. 2013, 87:7717-7725.
267. Yamamoto A.Y., Mussi-Pinhata M.M., Isaac Mde L., Amaral F.R., Carvalheiro C.G., Aragon D.C., Manfredi A.K., Boppana S.B., Britt W.J. Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population. Pediatr. Infect. Dis. J. 2011, 30:1043-1046.
268. Zhou M., Yu Q., Wechsler A., Ryckman B.J. Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J. Virol. 2013, 87:9680-9690.
269. Zhou T., Zhu J., Wu X., Moquin S., Zhang B., Acharya P., Georgiev I.S., Altae-Tran H.R., Chuang G.Y., Joyce M.G., Do Kwon Y., Longo N.S., Louder M.K., Luongo T., McKee K., Schramm C.A., Skinner J., Yang Y., Yang Z., Zhang Z., Zheng A., Bonsignori M., Haynes B.F., Scheid J.F., Nussenzweig M.C., Simek M., Burton D.R., Koff W.C., Program N.C.S., Mullikin J.C., Connors M., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013, 39:245-258.
270. Zhu J., Shearer G.M., Marincola F.M., Norman J.E., Rott D., Zou J.P., Epstein S.E. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1-type dominant response. Int. Immunol. 2001, 13:785-790.
271. Zurawski V.R., Haber E., Black P.H. Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines. Science 1978, 199:1439-1441.
272. Zydek M., Petitt M., Fang-Hoover J., Adler B., Kauvar L.M., Pereira L., Tabata T. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses 2014, 6:1346-1364.